Essentials Diabète: Faits saillants du 71e sessions

Essentials Diabète: Faits saillants du 71e
sessions scientiques CME
Supported by an independent educational grant from
View this activity online at:
medscape.org/lecture/diabetes-fr
and

Pg.2
Diabetes Essentials: Höhepunkte aus der 71. Scientic Sessions CME
This article is a CME/CE certied activity.
To earn credit for this activity visit:
medscape.org/lecture/diabetes-fr
CME/CE Released: 07/13/2011; Valid for credit through 07/13/2012
Target Audience
This activity is intended for endocrinologists, diabetologists, family medicine and internal medicine physicians, and allied
healthcare professionals (nurse practitioners, physician assistants, and diabetes educators) who treat patients with type 2 diabetes
Goal
The goal of this activity is to provide healthcare providers with expert perspectives and education on new data released at the
ADA Scientic Sessions on emerging therapies in type 2 diabetes and their clinical application to improve the management of
patients with diabetes.
Learning Objectives
Upon completion of this activity, participants will be able to:
1. Interpret new clinical trial data on emerging antidiabetic agents and novel therapeutic approaches to comprehensive
diabetes management
Credits Available
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing continuing education credit for this activity will be issued a certicate of
participation.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation Statements
This education initiative is in collaboration with the American Diabetes Association’s: 71st Scientic Sessions,
June 24 – 28 – 2011– San Diego, CA
For Physicians
Medscape, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians.
Medscape, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC sta have disclosed that they have no relevant nancial relationships.
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and
acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits
that reect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during

medscape.org/lecture/diabetes-fr
Pg.3
the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score
of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
1. Read the target audience, learning objectives, and author disclosures.
2. Study the educational content online or printed out.
3. Online, choose the best answer to each test question. To receive a certicate, you must receive a passing score as designated
at the top of the test. Medscape Education encourages you to complete the Activity Evaluation to provide feedback for
future programming.
You may now view or print the certicate from your CME/CE Tracker. You may print the certicate but you cannot alter it. Credits
will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as
well as the certicates by accessing “Edit Your Prole” at the top of your Medscape homepage.
*The credit that you receive is based on your user prole.
Hardware/Software Requirements
To access Medscape Education users will need
• A computer with an Internet connection.
• Internet Explorer 6.x or higher, Firefox 2.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
• Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback.
• Occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
Authors and Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an
education activity to disclose all relevant nancial relationships with any commercial interest. The ACCME denes “relevant
nancial relationships” as nancial relationships in any amount, occurring within the past 12 months, including nancial
relationships of a spouse or life partner, that could create a conict of interest.
Medscape, LLC, encourages Authors to identify investigational products or o-label uses of products regulated by the US Food
and Drug Administration, at rst mention and where appropriate in the content.
Author
Mark E. Molitch, MD
Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Disclosure: Mark E. Molitch, MD, has disclosed the following relevant nancial relationships:
Served as an advisor or consultant for: sano-aventis; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Corcept
Therapeutics Inc.
Received grants for clinical research from: sano-aventis; Novartis Pharmaceuticals Corporation; Corcept Therapeutics Inc.; Ipsen;
Reata Pharmaceuticals, Inc.
Dr. Molitch does intend to discuss o-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the US Food
and Drug Administration (FDA) for use in the United States.
Dr. Molitch does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA
for use in the United States.
Editor
Anne G. Le, PharmD, RPh
Scientic Director, Medscape, LLC
Disclosure: Anne G. Le, PharmD, RPh, has disclosed no relevant nancial relationships.
CME Reviewer
Nafeez Zawahir, MD
CME Clinical Director, Medscape, LLC
Disclosure: Nafeez Zawahir, MD, has disclosed no relevant nancial relationships.

Pg.4
Diabetes Essentials: Höhepunkte aus der 71. Scientic Sessions CME
Note du rédacteur: Ce programme comprend des discussions sur les agents d’investigation n’est pas approuvé par la Food and Drug
Administration américaine (FDA) pour une utilisation aux États-Unis et o-label utilisations de médicaments approuvés par la FDA pour
une utilisation aux États-Unis.
Einführung
Dr Mark E. Molitch: Bonjour, Je suis le Dr Mark Molitch. Je suis professeur de médecine à l’école de médecine Feinberg de
l’université du Nord-Ouest à Chicago, dans l’Illinois. Je suis ravi de vous accueillir à ce programme intitulé “Le diabète au quotidien :
points principaux essentiels de l’ADA (Association Américaine contre le Diabète).
La discussion d’aujourd’hui a pour objet principal de fournir un contexte clinique aux données présentées récemment lors des 71e
Sessions scientiques de l’ADA sur les traitements émergents du diabète de type 2 en prêtant plus particulièrement attention aux
traitements à base d’incrétine et aux inhibiteurs du SGLT-2 (transporteur sodium/glucose de type 2) encore à l’étude.

medscape.org/lecture/diabetes-fr
Pg.5
Nous nous servirons également de mini sondages interactifs an de mieux comprendre votre pratique clinique et votre niveau de
compréhension des traitements plus récents du diabète de type 2.
Avant de commencer, j’aimerais vous faire remarquer que cette activité comprendra une discussion sur les médicaments à l’étude
qui n’ont pas encore été approuvés par la FDA. Nous allons discuter d’études publiées sous forme d’abrégés et présentées lors des
Sessions scientiques de l’ADA de 2011. Ces études et les données qui leur correspondent doivent par conséquent être
considérées comme préliminaires jusqu’à ce qu’elles fassent l’objet d’une publication dans une revue spécialisée.